Investor Overview

Webcast ImageWebcast
AtriCure, Inc. at the Canaccord 2014 Medical Technologies & Diagnostics Forum  (Replay)
11/20/14 at 8:30 a.m. ET
Webcast ImageWebcast
AtriCure, Inc. at the Stifel Healthcare Conference 2014  (Replay)
11/18/14 at 3:35 p.m. ET
Webcast ImageWebcast
Q3 2014 AtriCure, Inc. Earnings Conference Call (Replay)
10/30/14 at 4:30 p.m. ET

Corporate Profile

AtriCure was formed by a team with extensive experience in the medical device industry. The company is focused on developing innovative products using proprietary technology that provides doctors alternative, expedient methods to ablate tissue during surgical procedures.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$18.73 - 0.130.69%76,570
Previous CloseToday's OpenIntraday HighIntraday Low
$18.86$18.86$19.08$18.63
Exchange: NASDAQ (US Dollar)
11/28/14 1:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
11/14/14
Download Documentation Investor Presentation
10/30/14
Download Documentation Q3 Earnings Call Transcript
04/11/14
Download Documentation 2013 Annual Report

All Recent News

DateTitle 
11/03/14AtriCure Receives FDA Approval For Pivotal Study to Enroll Non-Paroxysmal Afib Patients
AtriCure will investigate a minimally invasive approach to treat patients with persistent or long-standing persistent atrial fibrillation who have failed antiarrhythmic drug therapy. WEST CHESTER, Ohio--(BUSINESS WIRE) November 3, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced it has received approval for an Investigational Device Exemption from the U.S. Food and Drug A... 
Printer Friendly Version
10/31/14AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 31, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Stifel Healthcare Conference 2014 at the Palace Hotel in New York City on Tuesday, November 18, 2014. Management is scheduled to present at 3:35 p.m. Eastern Time. A live audio webcast and replay of the presentation will be a... 
Printer Friendly Version
10/30/14AtriCure Reports Third Quarter 2014 Financial Results and Updates 2014 Outlook
Revenue of $26.7 million – up 32.4% U.S. sales of $20.1 million – up 26.7% International sales of $6.6 million – up 53.4%; 53.9% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 30, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (“Afib”) and Left Atrial Appendage Management (“LAAM”), today announced financial results for the third ... 
Printer Friendly Version
10/09/14AtriCure Completes Enrollment in Post Approval Study for the Synergy™ Ablation System
This is the largest study of its kind to evaluate surgical ablation for the treatment of chronic Afib WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 9, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced enrollment in the ABLATE Post Approval Study (PAS) is complete. As of October 3, 2014, the ABLATE PAS enrolled 3... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
11/03/14AtriCure Receives FDA Approval For Pivotal Study to Enroll Non-Paroxysmal Afib Patients
AtriCure will investigate a minimally invasive approach to treat patients with persistent or long-standing persistent atrial fibrillation who have failed antiarrhythmic drug therapy. WEST CHESTER, Ohio--(BUSINESS WIRE) November 3, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced it has received approval for an Investigational Device Exemption from the U.S. Food and Drug A... 
Printer Friendly Version
10/31/14AtriCure Announces Upcoming Investor Conference Schedule
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 31, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Stifel Healthcare Conference 2014 at the Palace Hotel in New York City on Tuesday, November 18, 2014. Management is scheduled to present at 3:35 p.m. Eastern Time. A live audio webcast and replay of the presentation will be a... 
Printer Friendly Version
10/30/14AtriCure Reports Third Quarter 2014 Financial Results and Updates 2014 Outlook
Revenue of $26.7 million – up 32.4% U.S. sales of $20.1 million – up 26.7% International sales of $6.6 million – up 53.4%; 53.9% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 30, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (“Afib”) and Left Atrial Appendage Management (“LAAM”), today announced financial results for the third ... 
Printer Friendly Version
10/09/14AtriCure Completes Enrollment in Post Approval Study for the Synergy™ Ablation System
This is the largest study of its kind to evaluate surgical ablation for the treatment of chronic Afib WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 9, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced enrollment in the ABLATE Post Approval Study (PAS) is complete. As of October 3, 2014, the ABLATE PAS enrolled 3... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
10/01/13In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in th... 
Printer Friendly Version
06/18/13Promising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery
Patients show three-year freedom from atrial fibrillation, anti-arrhythmic drugs PRAGUE--(BUSINESS WIRE)--Jun. 18, 2013-- A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation (Afib) during last week’s International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) meeting being held in Prague, Czech Republic. At three-year follow-up, 80 percen... 
Printer Friendly Version
  More International News >>

Company Calendar

DateTitle
12/03/14 
11:00 a.m. ET
AtriCure, Inc. at the Piper Jaffray 26th Annual Healthcare Conference
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.